Management of clinical risks deriving from insertional mutagenesis

  • Email
  • Help
Current version

Reflection paper

Reference numberCAT/190186/2012
KeywordsGene therapy medicinal products, insertional mutagenesis, integration
DescriptionThis document discusses the factors contributing to genotoxicity of vector integration, the strategies to reduce the risk associated to insertional mutagenesis and the assays to evaluate vector oncogenesis at the pre-clinical and clinical level.

Related content

How helpful is this page?

Average rating:

 Based on 25 ratings

Add your rating:

See all ratings
5 ratings
5 ratings
5 ratings
5 ratings
5 ratings

Tell us more